Isabel Rodriguez-Barraquer, MD, PhD

Assistant Professor In Res

HIV, Infectious Disease, and Global Medicine, Infectious Diseases

My research focuses in applying novel epidemiological and statistical methods to understand the dynamics of infectious diseases and inform control interventions. While I am interested in infectious diseases generally, most of my work has focused on understanding shifts in the epidemiology of vector borne diseases including dengue, leishmaniasis, chikungunya, malaria and Zika.

MHS, 08/2012 - Biostatistics, Johns Hopkins University
PhD, 08/2012 - Epidemiology, Johns Hopkins University
MD, 06/2005 - Medicine, Pontificia Universidad Javeriana
  1. Opportunities for improved surveillance and control of dengue from age-specific case data.
  2. Nationally-representative serostudy of dengue in Bangladesh allows generalizable disease burden estimates.
  3. Impact of microscopic and submicroscopic parasitemia during pregnancy on placental malaria in a high-transmission setting in Uganda.
  4. Persistent parasitemia despite dramatic reduction in malaria incidence after 3 rounds of indoor residual spraying in Tororo, Uganda.
  5. Long-term circulation of Zika virus in Thailand: an observational study.
  6. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region.
  7. Dengue pre-vaccination screening and positive predictive values.
  8. Heterogeneous exposure and hotspots for malaria vectors at three study sites in Uganda.
  9. Taking Sharper Pictures of Malaria with CAMERAs: Combined Antibodies to Measure Exposure Recency Assays.
  10. Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus.
  11. Dynamics and determinants of the force of infection of dengue virus from 1994 to 2015 in Managua, Nicaragua.
  12. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure.
  13. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial.
  14. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk.
  15. Spatiotemporal incidence of Zika and associated environmental drivers for the 2015-2016 epidemic in Colombia.
  16. High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan.
  17. Impact of interventions and the incidence of ebola virus disease in Liberia-implications for future epidemics.
  18. The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
  19. Impact of interventions and the incidence of ebola virus disease in Liberia-implications for future epidemics.
  20. Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment.
  21. Quantifying Heterogeneous Malaria Exposure and Clinical Protection in a Cohort of Ugandan Children.
  22. Assessing the global threat from Zika virus.
  23. Dependability of results in conference abstracts of randomized controlled trials in ophthalmology and author financial conflicts of interest as a factor associated with full publication.
  24. Dengue Vaccine in Regions of Endemic Disease.
  25. Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection.
  26. Enhancing disease surveillance with novel data streams: challenges and opportunities.
  27. Reconstruction of 60 Years of Chikungunya Epidemiology in the Philippines Demonstrates Episodic and Focal Transmission.
  28. The Hidden Burden of Dengue and Chikungunya in Chennai, India.
  29. Differential efficacy of dengue vaccine by immune status.
  30. Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum.
  31. Estimating Potential Incidence of MERS-CoV Associated with Hajj Pilgrims to Saudi Arabia, 2014.
  32. Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development.
  33. Potential opportunities and perils of imperfect dengue vaccines.
  34. Revisiting Rayong: shifting seroprofiles of dengue in Thailand and their implications for transmission and control.
  35. Challenges in the interpretation of dengue vaccine trial results.
  36. Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis.
  37. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
  38. From re-emergence to hyperendemicity: the natural history of the dengue epidemic in Brazil.
  39. Etiologic agent of an epidemic of cutaneous leishmaniasis in Tolima, Colombia.